Lajos Pusztai Selected Research

Breast Neoplasms (Breast Cancer)

10/2008	Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
06/2008	Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
03/2008	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
03/2008	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
01/2008	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
01/2008	Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses.
01/2008	Evaluation of biological pathways involved in chemotherapy response in breast cancer.
10/2007	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
07/2007	Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
07/2007	Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
05/2007	Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
04/2007	Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
02/2007	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
01/2007	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
01/2007	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
12/2006	DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
11/2006	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
10/2006	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
09/2006	Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
09/2006	Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
09/2006	Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy.
03/2006	Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.
01/2006	Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer.
12/2005	The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
11/2005	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
10/2005	Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
09/2005	Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
08/2005	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
06/2005	Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
06/2005	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
01/2005	Breast cancer biomarkers.
01/2005	Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer.
12/2004	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
11/2004	Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer.
03/2004	Breast cancer biomarkers and molecular medicine: part II.
01/2004	Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
11/2003	Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
09/2003	Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
09/2003	Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
09/2003	Breast cancer biomarkers and molecular medicine.
07/2003	Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
03/2003	Estrogen receptors and distinct patterns of breast cancer relapse.
01/2003	Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy.
11/2002	Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
04/2002	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Articles by Research Topic

Disease

45	Breast Neoplasms (Breast Cancer) 10/2008 - 04/2002
8	Carcinoma (Carcinomatosis) 08/2005 - 04/2003
2	Residual Neoplasm 07/2007 - 10/2006
2	Neoplasms (Cancer) 04/2004 - 07/2003
1	Noninfiltrating Intraductal Carcinoma (DCIS) 07/2007
1	Lobular Carcinoma 01/2007
1	Neoplasm Metastasis (Metastasis) 11/2005

Drug/Important Bio-Agent (IBA)

7	Paclitaxel (Taxol)FDA LinkGeneric 03/2008 - 06/2005
5	trastuzumab (Herceptin)FDA Link 01/2007 - 04/2002
4	Estrogens (Estrogen)FDA Link 10/2008 - 07/2003
4	Fluorouracil (Carac)FDA LinkGeneric 01/2007 - 04/2003
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2007 - 04/2003
4	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2006 - 04/2003
3	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2007 - 06/2005
3	Epirubicin (Ellence)FDA LinkGeneric 01/2007 - 06/2005
3	Biological Markers (Surrogate Marker)IBA 01/2005 - 09/2003
2	docetaxel (Taxotere)FDA Link 06/2008 - 04/2002
2	tau Proteins (tau Protein)IBA 04/2007 - 06/2005
1	DNA ProbesIBA 01/2008
1	HormonesIBA 05/2007
1	DNA (Deoxyribonucleic Acid)IBA 12/2006
1	Transcription Factors (Transcription Factor)IBA 12/2005
1	ParaffinIBA 10/2005
1	P-GlycoproteinIBA 08/2005
1	tariquidar (XR9576)IBA 08/2005
1	TaxoidsIBA 07/2004
1	Protein Kinases (Protein Kinase)IBA 02/2004
1	Proteins (Proteins, Gene)IBA 01/2004
1	Carrier Proteins (Binding Protein)IBA 11/2003
1	sulindac sulfone (exisulind)IBA 09/2003
1	capecitabine (Xeloda)FDA Link 09/2003
1	pegylated liposomal doxorubicinIBA 09/2003
1	gemcitabine FDA Link 09/2003
1	RNA (Ribonucleic Acid)IBA 06/2003
1	Estrogen ReceptorsIBA 03/2003

Therapy/Procedure

31	Drug Therapy (Chemotherapy) 03/2008 - 11/2002
5	Adjuvant Chemotherapy 10/2008 - 05/2004
3	Neoadjuvant Therapy 03/2008 - 06/2005